Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (6279)	1/20/2005 6:33:22 PM
From: Qualified Opinion	Respond to of 10345

I agree. It's good news for patients. - eom

To: rkrw who wrote (6279)	1/20/2005 6:53:44 PM
From: scaram(o)uche	Respond to of 10345

Yonsei Med J. 2004 Dec 31;45(6):991-7. FTY720: Mechanism of Action and Potential Benefit in Organ Transplantation. Brinkmann V. Novartis Pharma AG Transplantation Research WSJ-386.101, CH-4002 Basel, Switzerland. volker.brinkmann@pharma.novartis.com. FTY720 is a novel immunomodulator that has proven effective in animal models of transplantation and autoimmunity, has achieved promising results in Phase I and Phase II studies of renal transplantation in humans, and is currently undergoing phase III studies. FTY720 acts as a high-affinity agonist at the sphingosine 1-phosphate receptor-1 (S1P1), where it internalises the receptor and causes alterations to the normal circulation of lymphocytes between the blood and lymphoid tissue. Unlike conventional immunosuppressants, FTY720 does not impair the activation, proliferation or effector functions of T- and B-cells. Further development of FTY720 is in progress, including trials in autoimmune disorders as well as transplantation. This review summarises the mechanism of action of FTY720, its effects in models of transplantation and autoimmunity, and results from clinical trials in humans.